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Abstract
Background: Systemic inflammation is associated with reduced lung function in both healthy individuals and those with
chronic obstructive pulmonary disease (COPD). Whether systemic inflammation in healthy young adults is associated with
future impairment in lung health is uncertain.
Methodology/Principal Findings: We evaluated the association between plasma fibrinogen and C-reactive protein (CRP) in
young adults and lung function in the Coronary Artery Risk Development in Young Adults cohort study. Higher year 7
fibrinogen was associated with greater loss of forced vital capacity (FVC) between years 5 and 20 (439 mL in quartile 4 vs.
398 mL in quartile 1, P,0.001) and forced expiratory volume in 1 second (FEV1) (487 mL in quartile 4 vs. 446 mL in quartile
1, P,0.001) independent of cigarette smoking, body habitus, baseline lung function and demographic factors. Higher year 7
CRP was also associated with both greater loss of FVC (455 mL in quartile 4 vs. 390 mL in quartile 1, P,0.001) and FEV1
(491 mL in quartile 4 vs. 442 mL in quartile 1, P=0.001). Higher year 7 fibrinogen and CRP were associated with abnormal
FVC at year 20 (odds ratio (OR) per standard deviation 1.51 (95% confidence interval (CI): 1.30–1.75) for fibrinogen and 1.35
(95% CI: 1.14–1.59) for CRP). Higher year 5 fibrinogen was additionally associated with abnormal FEV1. A positive interaction
was observed between pack-years cigarette smoking and year 7 CRP for the COPD endpoint, and among participants with
greater than 10 pack-years of cigarette exposure, year 7 CRP was associated with greater odds of COPD at year 20 (OR per
standard deviation 1.53 (95% CI: 1.08–2.16).
Conclusion/Significance: Systemic inflammation in young adults is associated with abnormal lung function in middle age.
In particular, elevated CRP may identify vulnerability to COPD among individuals who smoke.
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Introduction
Among both healthy individuals and chronic obstructive
pulmonary disease (COPD) patients, an inverse association
between blood levels of fibrinogen and C-reactive protein (CRP)
and forced expiratory volume in 1 second (FEV1) has been
reported [1,2,3,4]. Recent data indicate that CRP and other
inflammation-sensitive proteins may be risk factors for COPD
[5,6]. However, conflicting information exists regarding the
relationship between systemic inflammation and lung function
over time in young adults, and the available data are somewhat
limited by small sample size [7], losses to follow-up [8], and short
follow-up periods [1,9]. Data from the Odense Schoolchild Study
recently demonstrated that higher levels of CRP at age 20 are
associated with greater reduction in FEV1 and FVC over nine
years, but the young age of the study population makes it difficult
to ascertain risk of future lung disease [10].
Extending our prior work which examined the short-term
relationship between fibrinogen and lung function over 5 years [9],
we explored the relationship between both CRP and fibrinogen
measured in young adults aged 23 to 37 years and lung function
measured over 15 years of followup in the Coronary Artery Risk
Development in Young Adults (CARDIA) cohort study. We
hypothesized that in young adults without lung disease, elevated
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associated with accelerated decline in lung function over 15 years
of follow-up as well as greater risk of COPD in middle age. This
hypothesis, if confirmed, would imply that young adults with
evidence of systemic inflammation are at increased risk for future
impairments in lung health.
Materials and Methods
Ethics statement
All CARDIA exams were approved by the institutional review
board at each site, and written informed consent was obtained
from all subjects.
Study population
The CARDIA Study is a cohort study of 5,115 participants
conducted in 4 U.S. cities [11]. The cohort has completed a total
of seven examinations: year 0 (1985–1986), year 2 (1987–1988),
year 5 (1990–1991), year 7 (1992–1993), year 10 (1995–1996),
year 15 (2000–2001), and year 20 (2005–2006). At the time of
enrollment, virtually all CARDIA participants were generally
healthy and free of any overt uncontrolled chronic medical
conditions [12]. 3,549 participants were examined in year 20 (a
retention rate of 72%). Participants were excluded from this
analysis if they reported asthma, were on asthma medication at
any of the exams, had missing or poor quality spirometry at year
20, missing CRP or fibrinogen at year 7, if pregnant at years 5, 7,
or 20, or if they were transgender. The exclusions are detailed in
Figure 1. The baseline characteristics of the 2,132 participants
who were included in this analysis were compared to the 2,983
who either did not attend the year 20 examination or were
excluded from the current analysis. Compared to those who were
excluded, those included were older (25.2 vs. 24.6 years), smoked
less (2.0 vs. 2.4 pack years), had lower BMI (24.2 vs. 24.7 kg/m
2),
more education (14.2 vs. 13.4 years), and higher FEV1 (99.2% vs.
96.8% predicted), FVC (101.0% vs. 100.0% predicted), and
FEV1/FVC (83.4% vs. 82.7%). Excluded participants were 60%
Black.
Laboratory measurements
The earliest time-point in CARDIA at which both fibrinogen
and CRP were measured is year 7. Fibrinogen was measured by a
BNII nephelometer (Dade Behring, Deerfield, IL). The intra- and
inter-assay coefficients of variation were 2.7 and 2.6% [13]. CRP
was measured using a BNII nephelometer (Dade Behring,
Deerfield, IL), with intra- and inter-assay coefficients of variation
ranging from 2.3% to 4.4%, and 2.1% to 5.7% [14].
Spirometry
Spirometry was performed at all exams except years 7 and 15.
Spirometry through year 10 was measured using a Collins Survey
8-liter water sealed spirometer and an Eagle II Microprocessor
(Warren E. Collins, Inc., Braintree, MA). At year 20, a dry rolling-
seal OMI spirometer (Viasys, Loma Linda, CA) was used. The
accuracy of each spirometer was validated using the Pulmonary
Waveform Generator (MH Custom Design and Manufacturing,
Midvale, UT). A comparability study performed on 25 human
Figure 1. Summary of the population from CARDIA included in the present analysis.
doi:10.1371/journal.pone.0011431.g001
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both spirometers demonstrated an average difference between the
Collins and OMI spirometers of 6 ml for forced vital capacity
(FVC) and 21 ml for (forced expiratory volume in 1 second) FEV1.
Standard quality control and testing procedures were maintained
according to American Thoracic Society (ATS)/European Respi-
ratory Society (ERS) guidelines [15,16,17,18].
Statistical analysis
Analysis was performed in both quartiles of fibrinogen or CRP
as well as with continuous data. Because the distribution of both
CRP and fibrinogen differ according to race and sex, year 7
fibrinogen and CRP levels were divided into race- and sex-specific
quartiles (Table 1).
To determine whether individuals in the highest and lowest year
7 fibrinogen and CRP quartiles remained in that quartile at year
20, we cross-tabulated the earlier and year 20 quartiles to measure
the percentage of those in a given quartile at year 7 who remained
in that quartile at year 20. We additionally determined the
Spearman rank correlation coefficient in all participants between
the earlier and year 20 time-points for both fibrinogen and CRP
level.
Multivariable linear regression was used to assess the associa-
tions between fibrinogen or CRP and change in lung function
from the year 5 to the year 20 examination (determined by
subtracting the year 20 FEV1 or FVC measurement from the year
5 measurement). Because it was not normally distributed, year 7
CRP was log transformed. Adjustment was made for race-sex
group, age, age-squared, height, and height-squared at year 20
[19], BMI at the time of fibrinogen or CRP measurement, change
in waist circumference from year 7 to year 20, cumulative pack-
years of cigarette smoking, and year 5 lung function.
Generalized estimating equations (GEE) were used to examine
trends in FEV1 and FVC as a function of age over the 15 years of
study. The GEE model included the following covariates: race-sex
group, exam year, study center, and time-dependent age, time-
dependent height and height-squared, year 5 waist circumference
and time-dependent change in waist circumference, time-depen-
dent cumulative pack-years of cigarette exposure, and quartiles of
fibrinogen or CRP. In one model, designed to provide a detailed
visual assessment of goodness of fit to linear slope over age, age
was categorized into 2-year age groups, adjusted mean lung
function values were computed for each of the 14 age groups
(starting with 23–24 year olds) for each quartile and plotted. In a
second model, age was treated as a continuous variable and
interactions between quartiles of fibrinogen or CRP and age were
included to assess whether age trends for quartile 4 differed from
quartile 1.
Logistic regression was used to assess the associations of
fibrinogen or CRP with year 20 spirometry values less than 80%
of the predicted value according to published race- and sex-specific
equations [19], COPD using the Global Initiative for Obstructive
Lung Disease (GOLD) definition of FEV1/FVC #0.70 [20], and a
non-specific spirometric abnormality defined by both FEV1 and
FVC ,80% predicted with a FEV1/FVC .0.70, a phenotype
that is not addressed in the GOLD guidelines. Adjustment was
made for study center, cigarettes smoked per day and BMI at the
time of fibrinogen or CRP measurement and waist circumference
and cumulative pack years of exposure to cigarettes at the time of
lung function measurement. Multiplicative interactions between
CRP and fibrinogen and cumulative pack years of exposure to
cigarettes were also determined, and when significant (p for the
interaction term ,0.05) stratification by smoking was performed.
When analyzed as a continuous variable, CRP was log
Table 1. Characteristics of the subjects included in this analysis at the time of fibrinogen and CRP (year 7) measurement.
a
Characteristic Fibrinogen Quartile (year 7) CRP Quartile (year 7)
1234 1 2 3 4
Sex- and race-specific
range (mean)*
































































Mean age in years (SD) 31.9 (3.5) 32.1 (3.7) 32.3 (3.5) 32.4 (3.5) 32.2 (3.6) 32.1 (3.5) 32.3 (3.5) 32.2 (3.6)
Female gender 54% 54% 54% 54% 54% 54% 54% 54%
Race
African-American 40% 41% 40% 40% 40% 41% 40% 40%
Caucasian 60% 59% 60% 60% 60% 59% 60% 60%
Education level
High school or less 22% 23% 24% 26% 21% 24% 23% 26%
More than high school 78% 77% 76% 74% 79% 76% 77% 74%




24.0 (3.7) 25.2 (4.4) 26.4 (4.9) 29.6 (7.0) 23.4 (3.4) 25.4 (4.0) 26.7 (5.0) 29.7 (7.0)
aFibrinogen expressed in mg/dL, CRP expressed in mg/mL.
doi:10.1371/journal.pone.0011431.t001
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linear in its parameters.
All statistical analyses were conducted using SAS for Windows,
release 9.2 (SAS Institute Inc., Cary, NC).
Results
Subject characteristics
The plasma levels for the race- and sex-specific year 7
fibrinogen and CRP quartiles and demographic characteristics of
the study population are included in Table 1. As expected, ever
smoking and higher BMI were associated with higher fibrinogen
and CRP. Because fibrinogen and CRP are both acute phase
reactants, we assessed whether individuals with high fibrinogen or
CRP at year 7 continued to have high levels at year 20. The
majority of participants in the highest and lowest quartiles of
fibrinogen or CRP at year 7 remained in that quartile at year 20
(Table 2).
Systemic inflammation in young adults and change in
lung function over 15 years
Higher year 7 fibrinogen as well as CRP were associated
with greater 15 year decline in both FVC and FEV1.
(Table 3).
Models of lung function with age and the interaction
with fibrinogen and CRP
The interaction between systemic inflammation in young adults
and age-related decline in lung function was assessed using
spirometry values from exam years 5, 10, and 20 in a GEE model.
For both year 7 fibrinogen and CRP, quartile 4 had a greater age-
related decline in FVC compared with quartile 1 (P value for the
age-fibrinogen quartile or age-CRP quartile interaction on decline
in lung function ,0.001). In contrast, there was no significant
interaction between age-related decline in FEV1 and fibrinogen or
CRP (Figure 2).
Systemic inflammation in young adults and abnormal
lung function 13–15 years later
Year 7 fibrinogen was associated with abnormal year 20 FVC
and FEV1, as well as the non-specific abnormality at year 20, but
not COPD (Table 4). Year 7 CRP was associated with abnormal
year 20 FVC, but not FEV1, the non-specific abnormality, or
COPD (Table 4). We did not observe an interaction between
fibrinogen and pack-years cigarette smoking on any outcomes. A
positive interaction was observed between CRP and pack-years
cigarette smoking on the COPD endpoint (but no other endpoints
related to CRP) prompting subsequent analysis of the association
between year 7 CRP and COPD stratified by smoking. Among
participants with 10 or more pack years of cigarette smoking,
higher year 7 CRP was associated with greater odds of COPD at
year 20 (Table 5).
To evaluate the effects of systemic inflammation independent of
baseline lung function, we repeated this analysis excluding
individuals with abnormal lung function at year 5: 87 participants
had abnormal year 5 FEV1, 53 had abnormal year 5 FVC, 52 had
COPD at year 5, and 40 had the non-specific abnormality at year
5 and were therefore excluded. The association between year 7
fibrinogen and year 20 FEV1 ,80% predicted was preserved
(odds ratio (OR) per standard deviation fibrinogen 1.38 (95%
confidence interval (CI): 1.17–1.63; P,0.001) as was the
association with year 20 FVC ,80% predicted (OR per standard
deviation fibrinogen 1.55 (95% CI: 1.31–1.83, P,0.001) and the
non-specific spirometry abnormality at year 20 (OR per standard
deviation fibrinogen 1.50 (95% CI: 1.16–1.70; P,0.001). In
addition, the association year 7 CRP with FVC ,80% predicted
at year 20 remained significant (OR per standard deviation log-
transformed CRP 1.33 (95% CI: 1.11–1.59; P=0.002). The
Table 2. Spearman rank correlation coefficients between year






% (95% CI) in
quartile 1 at
year 7 also in
quartile 1 at
year 20
% (95% CI) in
quartile 4 at




Male 0.56 54 (48, 61) 51 (45, 58)
Female 0.56 55 (49, 61) 53 (47, 50)
Fibrinogen
Male 0.51 53 (46, 59) 49 (42, 55)
Female 0.57 51 (45, 57) 54 (48, 60)
*P,0.001 for each correlation coefficient shown.
doi:10.1371/journal.pone.0011431.t002
Table 3. Adjusted loss of FVC and FEV1 from year 5 to year 20 across race-sex specific quartiles of year 7 fibrinogen and CRP as
well as linear regression coefficients for fibrinogen and log-transformed CRP as continuous variables.
*
Loss of Lung Function Fibrinogen Quartile (Year 7)
(Year 5 minus Year 20) 1 2 3 4 Beta
{ P
FEV1 (mL) 446 456 464 487 0.333 ,0.001
FVC (mL) 398 14 441 439 0.418 ,0.001
CRP Quartile (Year 7)
1 2 3 4 Beta
{ P
FEV1 (mL) 442 453 468 491 16.383 0.001
FVC (mL) 390 422 425 455 19.199 ,0.001
*Adjusted for center, race-sex group, age, age-squared, height, and height-squared at year 20 [19], BMI at the time of fibrinogen or CRP measurement, change in waist
circumference from year 7 to year 20, cumulative pack-years of cigarette smoking, and year 5 lung function.
{Multivariable linear regression coefficient for the prediction of change in lung function from year 5 to year 20 by year 7 fibrinogen or CRP.
doi:10.1371/journal.pone.0011431.t003
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CRP on the COPD endpoint remained significant (P for the log
transformed CRP x pack-years exposure interaction=0.04). We
also repeated the analysis of CRP and COPD stratified by smoking
excluding those with COPD at baseline. While no longer
statistically significant, the trend for the association between
CRP and COPD remained among participants with 10 or more
pack-years (OR per standard deviation log transformed CRP 1.36
(95% CI: 0.91, 2.03, P=0.14)).
Discussion
We report three major findings. First, greater systemic
inflammation in young adults is associated with greater decline
in lung function over 15 years as well as having abnormal lung
function 13 years later. Participants in the highest year 7
fibrinogen or CRP quartiles had greater FEV1 and FVC decline
compared to those with the lowest quartiles over 15 years of
follow-up. Second, higher levels of year 7 fibrinogen and CRP in
young adulthood are associated with greater risk of having an
abnormal FVC (fibrinogen and CRP) and FEV1 (fibrinogen) in
middle-age. Third, among participants who smoked 10 or more
pack-years of cigarettes, year 7 CRP is associated with increased
risk of having obstructive lung disease at year 20.
Cross-sectional studies have documented that increased system-
ic inflammation is associated with lower lung function in both
healthy adults and patients with COPD [1,2,3,21]. In older
populations, there appears to be an association between systemic
inflammation and risk of COPD. In a Dutch study of subjects 55
years of age and older, CRP was associated with increased risk of
incident COPD [6], and in a study of 5,247 healthy Swedish men
of mean age 46 years, a panel of inflammation sensitive plasma
proteins including CRP was associated with increased risk of
COPD hospitalization [5]. There are, however, limited and
Figure 2. Relationship between age, lung function and quartile of fibrinogen or CRP (measured at year 7). Spirometry exams
performed at CARDIA visits at years 5, 10, and 20 were used to determine a mean lung function for each 2 year age group across year 7 CRP or
fibrinogen quartiles, and slopes compared between the highest and lowest quartile groups. For both fibrinogen and CRP, the age-related decline in
FVC was significantly different between quartiles 1 and 4. There were no significant differences in the FEV1 across CRP or fibrinogen
quartiles.Covariates in the model include race-sex group, exam year, pack-years of cigarette exposure, and time-dependent age, time-dependent
height and height-squared, and year 5 waist circumference and time-dependent change in waist circumference.
doi:10.1371/journal.pone.0011431.g002
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tion and lung function change over time in young adults. Fogarty,
et al found no association between baseline CRP and decline in
lung function over nine years in 2,442 individuals aged 18–70
years [8]. Among 531 participants 20 to 44 years of age in the
European Community Respiratory Health Survey, increases in
CRP over an 8 year period were associated with greater annual
declines in FEV1, although there was no significant association
between baseline CRP and annual decline in FEV1 [7]. We
performed a previous analysis from CARDIA that found that
participants in the highest quartile of fibrinogen at year 5 of the
study had year 10 FEV1 and FVC values that were 45 ml and
67 ml lower than those in the lowest quartile [9]. We now extend
upon this prior work to document that both fibrinogen and CRP
in young adults are associated with accelerated decline in lung
function as well as abnormal lung function over 15 years of
followup.
The origins of elevated markers of systemic inflammation in the
CARDIA cohort are uncertain. One can speculate that early lung
inflammation resulting from environmental exposures beyond
cigarette smoking results in decreasing lung function over time.
These exposures could also be accompanied by increased levels of
plasma fibrinogen and CRP as the systemic response to the
primary locus of inflammation in the lung. Both cigarette smoke
and ambient particulate matter have a high burden of oxidant
molecules. When inhaled, these likely result in significant local
oxidant stress in the lung resulting in local increases in
proinflammatory gene expression [22]. Ambient particulate
matter has been shown to stimulate release of TNF-a as well as
other cytolines including granulocyte macrophage colony-stimu-
lated factor (GM-CSF), interleukin (IL)-6 and IL-1b by human
alveolar macrophages [23]. These cytokines may then ‘‘spill-over’’
into the systemic circulation where they induce production of
acute phase reactants such as fibrinogen and CRP. The absence of
samples collected directly from the lungs of CARDIA participants
which could then be correlated with CRP and fibrinogen in the
blood limits our ability to explore this possibility further in the
CARDIA cohort.
Alternatively, some individuals may have genetic variation that
results in high systemic inflammation which results in increased
risk of adverse health outcomes if they have the additional
exposure of cigarette smoking [24,25]. These individuals may have
Table 4. Adjusted odds ratios (95% CI) for FEV1 or FVC less than 80% predicted, COPD using the GOLD definition (FEV1/FVC #0.70)
or a non-specific spirometry abnormality (FEV1 and FVC ,80% with FEV1/FVC .0.70) at year 20 across race- and sex-specific
quartiles of year 7 fibrinogen and CRP and per standard deviation of fibrinogen or log-transformed CRP.
*
Spirometry Year 7 Fibrinogen Quartile Per SD
{
(year 20) N 1 2 3 4 (mg/dL) P
FEV1,80% 241 1.0 1.11 (0.71, 1.73) 1.49 (0.98, 2.26) 1.23 (0.79, 1.91) 1.37 (1.19, 1.59) ,0.001
FVC,80% 214 1.0 1.27 (0.77, 2.09) 2.02 (1.28, 3.21) 1.77 (1.09, 2.87) 1.51 (1.30, 1.75) ,0.001
COPD (GOLD) 126 1.0 0.72 (0.42, 1.22) 1.00 (0.61, 1.65) 0.87 (0.50, 1.51) 0.93 (0.75, 1.16) 0.51
Non-specific abnormality 149 1.0 1.10 (0.62, 1.97) 1.78 (1.05, 3.01) 1.27 (0.77, 2.23) 1.47 (1.19, 1.68) ,0.001
Year 7 CRP Quartile Per SD
{
N 1 234( mg/mL) P
FEV1 ,80% 241 1.0 0.79 (0.51, 1.22) 0.94 (0.62, 1.43) 0.98 (0.63, 1.51) 1.17 (1.00, 1.37) 0.05
FVC ,80% 214 1.0 0.89 (0.55, 1.44) 1.26 (0.80, 1.99) 1.36 (0.85, 2.17) 1.35 (1.14, 1.59) ,0.001
COPD (GOLD) 126 1.0 0.94 (0.56, 1.57) 0.90 (0.53, 1.54) 1.13 (0.66, 1.96) 0.98
{ (0.80, 1.21) 0.86
Non-specific abnormality 149 1.0 0.70 (0.41, 1.20) 0.82 (0.49, 1.39) 0.81 (0.47, 1.40) 1.14 (0.94, 1.39) 0.18
*Adjusted for center, cigarettes/d, BMI at the time of fibrinogen and CRP measurement, and waist circumference and cumulative pack-years of cigarette exposure at the
time of spirometry.
{Adjusted odds ratio per standard deviation of year 7 fibrinogen or log-transformed CRP.
{Test for CRP x pack-years cigarette exposure interaction significant (P=0.005).
doi:10.1371/journal.pone.0011431.t004
Table 5. Adjusted odds ratios (95% CI) for COPD using the GOLD definition (FEV1/FVC #0.70) at year 20 across race- and sex-
specific quartiles of year 7 CRP and per standard deviation of CRP stratified by pack-years cigarette exposure.
*
Pack-Years Year 7 CRP Quartile Per SD
{
Smoking N
{ 1 234( mg/mL) P
0 pack-years (N=1249) 53 1.0 0.66 (0.32, 1.38) 0.48 (0.21, 1.12) 0.72 (0.32, 1.60) 0.77 (0.55, 1.06) 0.11
1–9 pack-years (N=501) 26 1.0 1.11 (0.43, 2.88) 0.29 (0.06, 1.42) 0.95 (0.26, 3.52) 0.78 (0.46, 1.32) 0.35
10+ pack-years (N=382) 47 1.0 2.46 (0.60, 10.11) 5.01 (1.38, 18.22) 4.90 (1.29, 18.59) 1.53 (1.08, 2.16) 0.02
*Adjusted for center, cigarettes/day, and BMI at the time of CRP measurement, and waist circumference and cumulative pack-years of cigarette exposure at the time of
spirometry.
{Adjusted odds ratio for COPD per standard deviation of log-transformed year 7 CRP.
{Number of year 20 COPD cases in each smoking stratum.
doi:10.1371/journal.pone.0011431.t005
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exaggerated inflammatory responses in both the lung and systemic
compartments. We observed that among participants at the
highest risk for developing COPD (10 or more pack-years of
smoking cigarettes), those with higher CRP in young adulthood
had elevated risk of COPD in middle age. This indicates that
smoking in a vulnerable population (those with high CRP) might
confer an accelerated risk of obstructive lung disease, compared to
the elevated inflammatory marker alone. Regardless of whether
CRP elevation is the result of ‘‘spill-over’’ or reflective of an
‘‘inflammatory phenotype’’, it may be valuable as a marker to
identify those cigarette smokers who are at greatest risk of
developing COPD in the future.
In our study, CRP and fibrinogen were not consistently
associated with the same patterns of lung function change over
time. We found that year 7 fibrinogen and CRP were both
associated with low FVC at year 20, but fibrinogen was also
associated with abnormal FEV1 and the non-specific reduction in
both FEV1 and FVC with a preserved FEV1/FVC. In addition,
while there was an interaction between CRP and cigarette
smoking, fibrinogen was not associated with COPD and did not
interact with smoking. Fibrinogen, therefore, may be a marker of
individuals at risk for restrictive lung disease. Alternatively, in
non-smokers, high fibrinogen and CRP may mark risk for
accelerated age-related decline in lung function, without the
development of any specific lung disease. Both patterns and their
respective blood markers are of considerable interest since
reductions in both FEV1 and FVC in the absence of a diagnosis
of lung disease are associated with cardiovascular and metabolic
disease [3,26].
It has recently been advocated that COPD be incorporated into
the ‘‘chronic systemic inflammatory syndrome’’ [27]. This
syndrome-based approach relies on the concept that chronic
systemic inflammation underlies not only COPD, but also other
co-morbid conditions, including cardiovascular disease and the
metabolic syndrome [27]. Our data indicate that systemic
inflammation in young adults, particularly CRP in cigarette
smokers, is associated with future impairment in lung health,
prompting the hypothesis that the systemic inflammation that links
COPD with various co-morbidities may be detectable prior to the
onset of clinically overt disease.
The major strength of our study is the long-term followup of a
cohort with serial lung function measurements. In addition, the
age of the cohort at the year 20 examination allows us to begin to
evaluate whether accelerated decline in lung function that occurs
in association with high levels of systemic inflammation in young
adults which has been reported by others [10], and confirmed in
our present report, actually results in clinical disease. We
document that in the highest risk group (those with 10 or greater
pack years of cigarette smoking) CRP in young adults is associated
with the presence of COPD 13 years later.
We note some limitations in our study. CRP and fibrinogen
measurements were not measured at the baseline visit. However,
the relatively early measurement of fibrinogen and CRP (year 7)
compared to lung function measurement (year 20) ensures that
the exposure of systemic inflammation predated, by more than a
decade, our principle outcome measurements. While both
fibrinogen and CRP are acute phase reactants and the duration
of exposure can be called into question, we documented that
those in the highest and lowest quartiles at the early time point of
measurement tend to remain in those categories at later time
points. The absence of specimens that directly measure lung
inflammation in the cohort limits our ability to link the
inflammatory responses in the systemic and respiratory compart-
ments. Another limitation is the absence of post-bronchodilator
spirometry testing as well as a lack of information about static
lung volumes or lung imaging, which would provide insights into
the structural changes in the lungs of participants observed to
have physiologic abnormalities. In addition, although we have
adjusted for waist circumference at the time of lung function
measurement and BMI at the time of fibrinogen and CRP
measurement in all statistical models, our analysis remains
vulnerable to residual confounding due to possible associations
between obesity, lung function, and inflammation. Since both
increased levels of CRP and fibrinogen were associated at
baseline with increased BMI, the possibility that obesity plays a
critical role in the lung function–systemic inflammation relation-
ship remains a clear possibility. Indeed, obesity is associated with
high CRP and fibrinogen [28] and lower lung function [29] and
may provide another link between systemic inflammation and low
lung function.
In conclusion, among a generally healthy population of young
adults, higher levels of plasma fibrinogen and CRP are associated
with accelerated decline in lung function. In individuals who
smoke more than 10 pack-years of cigarettes, higher levels of CRP
during young adulthood are associated with greater risk of COPD
in middle age. These findings indicate that individuals with
increased systemic inflammation early in life may be at increased
risk for future impairments in lung health, and CRP, in particular,
may be a useful marker of vulnerability for COPD among
cigarette smokers.
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